BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Japanese Government Grants SHONIN to Itamar Medical Ltd.'s EndoPAT Device


7/20/2009 8:45:13 AM

CAESAREA, Israel--(BUSINESS WIRE)--Based upon adherence to the strictest international standards of quality and clinical trials proving the EndoPAT’s safety and efficacy, the Japanese government has granted SHONIN (“clearance”) to Itamar-Medical’s EndoPAT, paving the way to widespread use in Japan for diagnosing endothelial dysfunction, a key cause of cardiovascular disease.

Japan’s rigorous process by its Pharmaceuticals and Medical Device Agency (PMDA) is considered by many to be even tougher than the American FDA (which is often a prerequisite by PMDA). SHONIN by PMDA allows for direct importation and marketing in Japan, but is also necessary to get coverage by Japan’s National Health Insurance Plan.

“We are extremely pleased to receive the SHONIN approval from PMDA. We truly believe that this official approval by our government may be the start of a very bright future for the EndoPAT in Japan,” said Mr. Yasunori Noto, President of CCI Corporation, an Itamar-Medical distributor in Japan.

“The world is now beginning to discover the revolutionary insight offered by EndoPAT as part of the process in early detection and prevention of cardiovascular heart disease,” said Dr. Dov Rubin, Itamar’s President & CEO.

Endothelial dysfunction is the earliest detectable stage of cardiovascular disease. It precedes clinical symptoms by years, even decades. Multiple studies have demonstrated its key role in the development of atherosclerosis which leads to heart attacks, strokes and other fatal or debilitating diseases. Amazingly, it is highly responsive to treatment, and patients who improve their endothelial function have been shown to suffer a lower rate of cardiovascular events.

Hundreds of EndoPAT systems have been sold in over 40 countries. EndoPAT is used by prestigious medical centers such as Mayo Clinic, leading studies with thousands of participants such as Framingham Heart Study, and in many trials by pharmaceutical companies searching for new ways to treat and prevent heart disease as well as detecting adverse affects before they occur.

About Itamar Medical

Itamar Medical Ltd. is a publicly-traded medical technology company (TASE:ITMR) utilizing PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to both the cardiovascular and autonomic nervous systems. For more information, visit www.itamar-medical.com.

Contact:

Triwaks Public RelationsDaphna Triwaks, 972-50-5202322daphna@triwaks.co.il



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES